Researchers from the world’s top pharmaceutical companies will converge on Washington, D.C. in September for the 2026 Global Impact Conference, hosted by the Critical Path Institute (C-Path).
The conference, happening September 15-16, aims to tackle the pressing issue of how we generate evidence of a new medicine’s efficacy and safety. The pharmaceutical industry is still largely reliant on traditional methods, which can be slow, costly, and often inefficient.
Accelerating the Pace of Innovation
Speakers from C-Path and other leading organizations in the field will share their expertise and experiences in developing new approaches to evidence generation. These innovative methods could help to speed up the development and approval of new medicines, getting them to patients who need them faster.
Dr. Jose Davila-Fajardo, a renowned expert in pharmaceutical development, will deliver a keynote address on the current state of the industry and the potential benefits of a paradigm shift in evidence generation. “The traditional model is no longer fit for purpose,” he said. “We need to harness the latest advancements in technology and science to drive change.”
New Paradigms for Evidence Generation
The conference will also explore the challenges and opportunities associated with the use of artificial intelligence (AI) and machine learning (ML) in pharmaceutical development. Researchers from companies like Novartis and GlaxoSmithKline will discuss how these technologies can be leveraged to improve the efficiency and effectiveness of evidence generation.
By harnessing the power of AI and ML, researchers can analyze vast amounts of data more quickly and accurately than ever before. This can help to identify potential issues earlier in the development process, reducing the risk of costly delays and failed clinical trials.
What this means
The 2026 Global Impact Conference has the potential to accelerate the pace of innovation in pharmaceutical development. By establishing a new paradigm for evidence generation, researchers can develop new medicines more efficiently and get them to patients who need them faster. The ultimate goal is to improve patient outcomes and save lives – a challenge that the global pharmaceutical industry is eager to tackle.
